Squarepoint’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Squarepoint’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,950	Closed	-$134K	–	5638
2024 Q4	$134K	Sell	13,950 -98,315	-88%	-$513K	﹤0.01%	4617
2024 Q3	$321K	Buy	112,265 +29,628	+36%	+$91.7K	﹤0.01%	3400
2024 Q2	$241K	Buy	+82,637	New	+$226K	﹤0.01%	3553
2023 Q4	–	Sell	-222,315	Closed	-$529K	–	4606
2023 Q3	$529K	Sell	222,315 -7,685	-3%	-$16.1K	﹤0.01%	2764
2023 Q2	$405K	Buy	230,000 +58,155	+34%	+$149K	﹤0.01%	2767
2023 Q1	$529K	Buy	+171,845	New	+$1.03M	﹤0.01%	2264
2021 Q1	–	Sell	-12,234	Closed	-$134K	–	3723
2020 Q4	$134K	Buy	12,234 +969	+9%	+$10.2K	﹤0.01%	2646
2020 Q3	$100K	Buy	+11,265	New	+$128K	﹤0.01%	2285

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Squarepoint's PSTX Position: Q1 2025 in Review

Squarepoint sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 13,950 shares — an estimated $134K sold.

Squarepoint first reported a position in PSTX in Q3 2020 and held it in 8 quarters. The position peaked at $529K in Q1 2023. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Squarepoint reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Squarepoint sold 13,950 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $134K.
Squarepoint first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 8 quarters.
Squarepoint's Poseida Therapeutics, Inc. Common Stock position peaked at $529K in Q1 2023.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.